KRRO
Korro Bio, Inc.
$10.29
+0.53
(+5.48%)
Mkt Cap
99.43M
Volume
87,191
52W Range
5.2-55.89
Sector
Healthcare
Beta
2.36
EPS (TTM)
-10.01 USD
P/E Ratio
-0.64
Revenue (TTM)
2.38M USD
Rev Growth (5Y)
-29.6%
EPS Growth (5Y)
N/A
Company Description
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.39M | 2.27M | 0 | 0 | 0 | 36.98M | 28.95M | 0 | 0 |
| Net Income | (117.26M) | (83.58M) | (81.17M) | (58.03M) | (21.96M) | (26.51M) | (18.75M) | (19.17M) | (20.24M) |
| EPS | -12.48 | -9.37 | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Free Cash Flow | (79.08M) | (77.98M) | (75.12M) | (58.86M) | (36.54M) | (51.86M) | 33.15M | (17.46M) | (16.48M) |
| FCF / Share | -8.42 | -8.74 | -49.13 | -230.81 | -8.22 | -80.39 | 53.74 | -27.84 | -26.28 |
| Operating CF | (78.56M) | (60.07M) | (67.28M) | (53.65M) | (32.09M) | (45.19M) | 34.22M | (17.02M) | (14.61M) |
| Total Assets | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M | 264.72M | 223.22M | 44.55M | 19.79M |
| Total Debt | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M | 45.99M | 0 | 84.94M | 46.69M |
| Cash & Equiv | 21.82M | 55.64M | 166.15M | 36.94M | 79.64M | 220.34M | 200.16M | 42.19M | 17.94M |
| Book Value | 51.44M | 160.41M | 169.91M | (99.03M) | 130.82M | 192.49M | 167.36M | (48.28M) | (29.64M) |
| Return on Equity | -2.28 | -0.52 | -0.48 | N/A | -0.17 | -0.14 | -0.11 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.29M | 1.09M | 1.46M | 2.55M | 2.27M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (18.92M) | (19.62M) | (50.04M) | (18.06M) | (25.77M) | (23.39M) | (21.20M) | (21.00M) | (21.83M) | (19.56M) | (25.43M) | (18.49M) |
| EPS | -1.07 | -1.69 | -5.33 | -1.92 | -2.74 | -2.49 | -2.26 | -2.26 | -2.43 | -2.44 | -4.89 | -2.03 |
| Free Cash Flow | (17.03M) | (16.09M) | (17.79M) | (17.35M) | (19.37M) | (24.57M) | (8.95M) | (20.97M) | (20.55M) | (27.50M) | (47.66M) | (12.02M) |
| FCF / Share | -0.97 | -1.39 | -1.89 | -1.85 | -2.06 | -2.62 | -1.00 | -2.25 | -2.29 | -3.43 | -5.95 | -2.10 |
| Operating CF | (16.99M) | (16.07M) | (17.70M) | (17.18M) | (19.23M) | (24.45M) | (7.50M) | (16.09M) | (14.59M) | (21.89M) | (39.92M) | (11.77M) |
| Total Assets | 163.45M | 183.62M | 113.51M | 161.55M | 180.43M | 202.21M | 226.24M | 243.54M | 249.59M | 197.99M | 221.66M | 95.83M |
| Total Debt | 42.21M | 42.88M | 43.49M | 44.67M | 44.63M | 45.19M | 44.77M | 41.78M | 38.46M | 35.92M | 33.21M | 31.22M |
| Cash & Equiv | 24.91M | 61.70M | 21.82M | 25.16M | 33.61M | 64.14M | 55.64M | 63.21M | 91.15M | 138.80M | 166.15M | 46.12M |
| Book Value | 103.23M | 119.63M | 51.44M | 99.03M | 115.10M | 138.96M | 160.41M | 179.63M | 198.08M | 151.36M | 169.91M | 56.07M |
| Return on Equity | -0.18 | -0.16 | -0.97 | -0.18 | -0.22 | -0.17 | -0.13 | -0.12 | -0.11 | -0.13 | -0.15 | -0.33 |
KRRO News
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by Brokerages
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Moderate Buy” by Analysts
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)